Clinical trials: Digestive Neoplasms
Carcinoma, Colorectal
Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin…
- Trial name
- NCT01380600
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Jennerex Biotherapeutics
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma
- Trial name
- NCT02045602
- Testing
- VCN-01, Gemcitabine, Abraxane®
- Where
- 5 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Theriva Biologics SL
Esophageal Cancer
Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium
This study will evaluate the C2 CryoBalloon™ Full and Swipe Ablation Systems for the ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy for reasons unrelated to the objective of the study
- Trial name
- NCT02729753
- Testing
- CryoBalloon™ Full Ablation System, CryoBalloon™ Swipe Ablation System
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pentax Medical
Neoplasms, Gastrointestinal Tract
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
This was an international multi-center trial that enrolled patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors had amplification of the ErbB2 (HER2)…
- Trial name
- NCT00680901
- Testing
- Lapatinib, Capecitabine, Oxaliplatin
- Where
- 183 sites in United States, Argentina and 21 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer
Virulizin is an immunotherapy drug preparation that is thought to stimulate the patient's immune system, which in turn may slow the growth of tumors. It is presented in vials as a sterile preparation for IM injection.
- Trial name
- NCT00040092
- Testing
- Virulizin®
- Volunteers
- 400 people
- Sponsor
- Aptose Biosciences Inc.
Advanced Hepatocellular Carcinoma
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
- Trial name
- SIERRA (NCT05883644)
- Testing
- Durvalumab, Tremelimumab
- Where
- 40 sites in United States, France and 8 more
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.
Colorectal Cancer
Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
The purpose of this study is to determine whether S-1 and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer
- Trial name
- NCT00569699
- Testing
- S-1, Bevacizumab
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Pancreatic Cancer
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer.
- Trial name
- NCT01472198
- Testing
- Simtuzumab, Gemcitabine
- Where
- 57 sites in United States, Russia
- Volunteers
- 250 people
- Sponsor
- Gilead Sciences
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- SAPHIR (NCT04290806)
- Testing
- Routine care as per site standard
- Where
- Germany
- Volunteers
- 1,900 people
- Sponsor
- iOMEDICO AG
Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
- Trial name
- NCT01101906
- Testing
- OSI-906
- Where
- 41 sites in United States, Belgium and 8 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Inc
Gastrointestinal Tumors, Solid Tumors
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This is an open-label, multicenter, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-ARC002 Injection in patients with locally advanced or…
- Trial name
- NCT07763652
- Testing
- BL-ARC002
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Colorectal Neoplasms, Colonic Neoplasms
Study Evaluating EKB-569 in Advanced Colorectal Cancer
This non-randomized, open-label, outpatient clinical trial is designed to assess the safety and efficacy of daily orally administered EKB-569 in subjects with advanced colorectal cancer.
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00072748
- Testing
- EKB-569
- Volunteers
- 63 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Colorectal Cancer
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
The purposes of this study were to assess the safety, tolerability, pharmacokinetic interactions, and the Human Anti-Human Antibody of dalotuzumab in combination with cetuximab and irinotecan in participants with advanced or…
- Trial name
- NCT00925015
- Testing
- Dalotuzumab 10 mg/kg, Cetuximab, Irinotecan
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
This Phase II, multicenter, double-blind, randomized, active-controlled trial is designed to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) when administered at a dose of 5 mg/kg every 2 weeks in combination with 5 FU…
- Trial name
- NCT00109226
- Testing
- Avastin (Bevacizumab)
- Sponsor
- Genentech, Inc.
Carcinoma, Hepatocellular
GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
This study is an international prospective, open-label, multi-center, non-interventional study. The protocol will allow enrollment of all patients with diagnosis of HCC in whom a decision to treat with sorafenib has not been made…
- Trial name
- NCT01191385
- Testing
- Any treatment for unresectable HCC as chosen by the physician
- Where
- 24 sites in United States
- Sponsor
- Bayer
Biliary Tract Cancer
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 compared with the investigator's choice of protocol in patients with locally advanced or…
- Trial name
- NCT07582315
- Testing
- BL-B01D1, Oxaliplatin, Calcium levofolinate
- Where
- China
- Volunteers
- 538 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.